Bank of New York Mellon’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $74.3M | Buy |
|
|||||
|
2025
Q2 | $75.1M | Sell |
|
|||||
|
2025
Q1 | $97.5M | Sell |
|
|||||
|
2024
Q4 | $158M | Buy |
|
|||||
|
2024
Q3 | $163M | Sell |
|
|||||
|
2024
Q2 | $192M | Sell |
|
|||||
|
2024
Q1 | $230M | Buy |
|
|||||
|
2023
Q4 | $247M | Buy |
|
|||||
|
2023
Q3 | $212M | Buy |
|
|||||
|
2023
Q2 | $190M | Buy |
|
|||||
|
2023
Q1 | $202M | Buy |
|
|||||
|
2022
Q4 | $176M | Buy |
|
|||||
|
2022
Q3 | $97.1M | Sell |
|
|||||
|
2022
Q2 | $112M | Buy |
|
|||||
|
2022
Q1 | $57.3M | Buy |
|
|||||
|
2021
Q4 | $62.1M | Sell |
|
|||||
|
2021
Q3 | $54.5M | Buy |
|
|||||
|
2021
Q2 | $58M | Sell |
|
|||||
|
2021
Q1 | $53.5M | Sell |
|
|||||
|
2020
Q4 | $65.8M | Sell |
|
|||||
|
2020
Q3 | $62.8M | Sell |
|
|||||
|
2020
Q2 | $136M | Buy |
|
|||||
|
2020
Q1 | $63.3M | Buy |
|
|||||
|
2019
Q4 | $62.8M | Sell |
|
|||||
|
2019
Q3 | $51M | Sell |
|
|||||
|
2019
Q2 | $121M | Sell |
|
|||||
|
2019
Q1 | $130M | Sell |
|
|||||
|
2018
Q4 | $128M | Buy |
|
|||||
|
2018
Q3 | $129M | Sell |
|
|||||
|
2018
Q2 | $126M | Sell |
|
|||||
|
2018
Q1 | $115M | Sell |
|
|||||
|
2017
Q4 | $130M | Sell |
|
|||||
|
2017
Q3 | $172M | Sell |
|
|||||
|
2017
Q2 | $215M | Buy |
|
|||||
|
2017
Q1 | $200M | Buy |
|
|||||
|
2016
Q4 | $184M | Buy |
|
|||||
|
2016
Q3 | $194M | Buy |
|
|||||
|
2016
Q2 | $141M | Buy |
|
|||||
|
2016
Q1 | $121M | Buy |
|
|||||
|
2015
Q4 | $108M | Buy |
|
|||||
|
2015
Q3 | $108M | Sell |
|
|||||
|
2015
Q2 | $142M | Buy |
|
|||||
|
2015
Q1 | $125M | Buy |
|
|||||
|
2014
Q4 | $54.3M | Buy |
|
|||||
|
2014
Q3 | $43M | Sell |
|
|||||
|
2014
Q2 | $37.8M | Buy |
|
|||||
|
2014
Q1 | $41M | Sell |
|
|||||
|
2013
Q4 | $42.6M | Sell |
|
|||||
|
2013
Q3 | $46.7M | Sell |
|
|||||
|
2013
Q2 | $42.2M | Buy |
|